Silvana Canevari
- Oncology top 0.5%
- CAR-T cell therapy research 16
- HER2/EGFR in Cancer Research 14
- Immunology top 1%
- Immunotherapy and Immune Responses 33
- Toxin Mechanisms and Immunotoxins 20
- Cancer Research top 1%
-
- Monoclonal and Polyclonal Antibodies Research 86
- Radiopharmaceutical Chemistry and Applications 22
- Reproductive Medicine top 1%
- Ovarian cancer diagnosis and treatment 21
-
- Glycosylation and Glycoproteins Research 29
- Co-authors
- Delia MezzanzanicaMaria I. ColnaghiSilvia MiottiSylvie MénardMarina BagnoliMariangela FiginiAntonella TomassettiLoris De Cecco
- Cited by
- OncologyImmunologyCancer Research
- Journals
- International Journal of Cancer (18 papers)Oncotarget (11 papers)Cancer Immunology Immunotherapy (9 papers)
- Partner nations
- ItalyUnited StatesGermany
In The Last Decade
Silvana Canevari
224 papers receiving 8.5k citations
Hit Papers
Peers
Comparison fields: 5 of 143
- Oncology 3.2k
- Immunology 2.2k
- Cancer Research 1.4k
- Radiology, Nuclear Medicine and Imaging 1.9k
- Reproductive Medicine 583
Countries citing papers authored by Silvana Canevari
This map shows the geographic impact of Silvana Canevari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Silvana Canevari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Silvana Canevari more than expected).
Fields of papers citing papers by Silvana Canevari
This network shows the impact of papers produced by Silvana Canevari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Silvana Canevari. The network helps show where Silvana Canevari may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Silvana Canevari, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 4 | |
| 2 | 2020 | 2 | |
| 3 | 2019 | 10 | |
| 4 | 2018 | 10 | |
| 5 | 2018 | 23 | |
| 6 | 2016 | 53 | |
| 7 | Antibody Engineering as Opportunity for Selection and Optimization of Anti- HIV Therapeutic Agents | 2010 | 1 |
| 8 | 2008 | 84 | |
| 9 | 2008 | 98 | |
| 10 | 2008 | 98 | |
| 11 | 2006 | 31 | |
| 12 | 2006 | 73 | |
| 13 | 2004 | 20 | |
| 14 | Induction of a multifactorial resistance phenotype by high paclitaxel selective pressure in a human ovarian carcinoma cell line. | 2004 | 7 |
| 15 | 2001 | 8 | |
| 16 | 1999 | 35 | |
| 17 | 1995 | 37 | |
| 18 | 1992 | 3 | |
| 19 | 1988 | 1 | |
| 20 | 1986 | 8 |
About Silvana Canevari
Silvana Canevari is a scholar working on Radiology, Nuclear Medicine and Imaging, Immunology, Reproductive Medicine, Oncology and Cancer Research, having authored 227 papers that have together received 8.7k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (86 papers), Immunotherapy and Immune Responses (33 papers), Glycosylation and Glycoproteins Research (29 papers), Radiopharmaceutical Chemistry and Applications (22 papers), Ovarian cancer diagnosis and treatment (21 papers), Toxin Mechanisms and Immunotoxins (20 papers), CAR-T cell therapy research (16 papers) and HER2/EGFR in Cancer Research (14 papers). The work is most often cited by research in Oncology (3.2k citations), Immunology (2.2k citations), Cancer Research (1.4k citations), Radiology, Nuclear Medicine and Imaging (1.9k citations) and Reproductive Medicine (583 citations). Silvana Canevari has collaborated with scholars based in Italy, United States and Germany. Frequent co-authors include Delia Mezzanzanica, Maria I. Colnaghi, Silvia Miotti, Sylvie Ménard, Marina Bagnoli, Mariangela Figini, Antonella Tomassetti, Loris De Cecco, Elda Tagliabue and Egidio Iorio. Their work appears in journals such as International Journal of Cancer, Oncotarget, Cancer Immunology Immunotherapy, PLoS ONE and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.